109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
For patients navigating the aftermath of early-stage breast cancer, the transition from intensive hospital-based treatment to long-term maintenance is often a period of profound anxiety. The … Read more